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Abstract
Background: A subset of horses deficient in alpha-tocopherol (α-TP) develop muscle
atrophy and vitamin E-responsive myopathy (VEM) characterized by mitochondrial
alterations in the sacrocaudalis dorsalis medialis muscle (SC).
Objectives: To quantify muscle histopathologic abnormalities in subclinical α-TP defi-
cient horses before and after α-TP supplementation and compare with retrospective
(r)VEM cases.
Animals: Prospective study; 16 healthy α-TP-deficient Quarter Horses. Retrospec-
tive study; 10 retrospective vitamin E-responsive myopathy (rVEM) cases .
Methods: Blood, SC, and gluteus medius (GM) biopsy specimens were obtained before
(day 0) and 56 days after 5000 IU/450 kg horse/day PO water dispersible liquid α-TP
(n = 8) or control (n = 8). Muscle fiber morphology and mitochondrial alterations were
compared in samples from days 0 and 56 and in rVEM cases.
Results: Mitochondrial alterations more common than our reference range
(<2.5% affected fibers) were present in 3/8 control and 4/8 treatment horses
on day 0 in SC but not in GM (mean, 2.2; range, 0%-10% of fibers). Supplemen-
tation with α-TP for 56 days did not change the percentage of fibers with mito-
chondrial alterations or anguloid atrophy, or fiber size in GM or SC. Clinical
rVEM horses had significantly more mitochondrial alterations (rVEM SC, 13%
± 7%; GM, 3% ± 2%) and anguloid atrophy compared to subclinical day
0 horses.
Conclusions and Clinical Importance: Clinically normal α-TP-deficient horses can
have mitochondrial alterations in the SC that are less severe than in atrophied VEM
cases and do not resolve after 56 days of α-TP supplementation. Preventing α-TP
deficiency may be of long-term importance for mitochondrial viability.
Abbreviations: 3D, 3-dimensional; C, control group; EM, electron microscopy; EMND, equine motor neuron disease; eNAD, equine neuroaxonal dystrophy; GM, gluteus medius; HE, hematoxylin
and eosin; NADH-TR, nicotinamide adenine dinucleotide tetrazolium reductase; rVEM, retrospective vitamin E-responsive myopathy; SC, sacrocaudalis dorsalis medialis muscle; SDH, succinate
dehydrogenase; Tx, α-TP treatment group; VEM, vitamin E-responsive myopathy; α-TP, alpha-tocopherol.
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1 | INTRODUCTION
Vitamin E is an essential fat-soluble vitamin that prevents cyclic prop-
agation of lipid peroxidation and stabilizes membranes and with lesser
known functions in cellular transport, cell signaling, and gene tran-
scription.1,2 Vitamin E comprises both tocopherols (saturated) and
tocotrienols (unsaturated) with the most biologically active isoform,
alpha-tocopherol (α-TP), often administered as a dietary supplement
in synthetic or highly bioavailable natural formulations.1,3,4
Dietary deficiency of α-TP in horses usually arises from a lack of
access to fresh grass.5,6 Rigorous competition schedules, overcrowding,
overgrazing, and drought conditions limit pasture access and therefore
increase the risk of α-TP deficiency. Alpha-TP concentrations in hay
begin to decrease after a few months of storage, and concentrates for
horses are fortified with the less bioavailable synthetic α-TP.7,8 Thus,
over time, horses without pasture access are at risk for α-TP deficiency.
Serum α-TP >2 μg/mL often is used as the reference range, but most
grazing horses maintain serum α-TP concentrations between 3 and
7 μg/mL.6
Diseases known to be associated with α-TP deficiency include the
upper motor neuron disorders equine neuroaxonal dystrophy (eNAD)/
equine degenerative myeloencephalopathy and the lower motor neu-
ron disorder equine motor neuron disease (EMND).6,9,10 The reason
why specific clinical signs and localized histopathology develop in
some horses with α-TP deficiency and not others is unclear. Potential
explanations include the timing and duration of α-TP deficiency,
genetic predisposition, and other environmental or nutritional fac-
tors.10-14 For example, prerequisites for development of eNAD appear
to be a genetic predisposition as well as temporal exposure to low
amounts of α-TP as foals.11,13 In contrast, years of α-TP deficiency
may be required for development of EMND.5 Many horses with low
serum α-TP concentration, however, do not appear to develop neuro-
muscular disease, leaving owners to debate the necessity of providing
α-TP supplementation for their horses.
Recently, a myopathy has been described in adult horses, which is
responsive to α-TP called vitamin E-responsive myopathy (VEM).15
Similar to EMND, VEM presents as an insidious onset of poor perfor-
mance, muscular weakness, and grossly apparent muscle atrophy.15
Distinct from EMND, mitochondrial stains of the sacrocaudalis dors-
alis medialis muscle (SC) from horses with VEM show a hallmark
“moth-eaten” staining pattern in muscle fibers and a preponderance
of anguloid rather than the angular muscle fiber atrophy seen in
EMND.15,16 Anguloid atrophied fibers are common with myogenic
atrophy and characterized by concavity on ≥1 sides. Angular atrophy
is common with motor nerve damage and is characterized by a smaller
fiber size with pronounced triangular shape.17 In contrast to the pro-
gressive nature of EMND, horses with VEM often regain muscle mass
and return to their previous level of performance within 3 months of
α-TP supplementation.5,6,15 Vitamin E-responsive myopathy could be
either a precursor to EMND or potentially a separate myopathic disor-
der characterized by grossly apparent muscle atrophy.
Determination of whether apparently healthy horses with α-TP
deficiency have subclinical evidence of VEM or EMND in skeletal
muscle would inform horse owners of potential benefits to providing
α-TP supplementation. We hypothesized that myogenic atrophy and
mitochondrial alterations would be present in the SC muscle of appar-
ently healthy horses deficient in α-TP and that lesions would be ame-
liorated by 8 weeks of α-TP supplementation. The first aim of our
prospective study was to quantify histopathologic alterations in SC
and gluteus medius (GM) of α-TP-deficient horses that had no appar-
ent signs of neuromuscular disease. The second aim was to determine
if α-TP supplementation over 8 weeks would ameliorate any histo-
pathologic alterations and increase muscle volume. The final aim was
to compare the severity of SC and GM histopathology between
horses in the prospective study with a retrospective group of horses
with VEM that had clinical signs of muscle atrophy, weakness, and
potentially altered gait.
2 | MATERIALS AND METHODS
2.1 | Prospective study
2.1.1 | Horses
Sixteen unfit Quarter Horse types owned by the University of California,
Davis, that had no evidence of neuromuscular disease, were included in
the study. Horses were housed at an accredited facility andwere cared for
according to the guidelines of the Animal Use and Care Committees at the
University of California, Davis, and Michigan State University. Horses had
been maintained in dry lots and fed grass hay with no additional supple-
mentation for 5 months before the study. Before the trial, serum α-TP
concentrations were measured and horses were selected for inclusion if
they had concentrations <3 μg/mL.6 Fifteen of 16 horses had serum
α-TP < 2 μg/mL, with 1 horse at 2.2 μg/mL. Horses were divided into
2 groups based on sex and pretrial serum α-TP concentrations: untreated
control (C; 3 geldings, 5 mares; 12.4 ± 3.1 years of age; enrollment serum
α-TP, 0.72 ± 0.65 μg/mL) and α-TP treatment (Tx; 3 geldings, 5 mares;
11.9 ± 2.5 years of age; serum α-TP, 0.52 ± 0.36 μg/mL). Serum α-TP
<3 μg/mLwas confirmed on day 0 for all enrolled horses.
2.1.2 | Study design
On day 0, blood samples were collected, horses were weighed and
received physical and neurologic examinations, a 3-dimensional
(3D) infrared scan for body volume was performed, and muscle biopsy
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specimens were obtained from SC and GM.18 Between days 0 and
56, horses were housed in dry lots and fed 1st cutting grass hay
(1.5%-2% of body weight), and 0.5 kg/day of alfalfa pellets (Harlan
Feed Alfalfa Pellets, Woodland, California) using over-the-nose feed
bags. Horses in the Tx group received 5000 IU/day liquid water-
dispersible natural form of vitamin E with stereoisomer RRR-α-TP
(Nano-E, Kentucky Equine Research, Versailles, Kentucky) top-dressed
onto the alfalfa pellets. When all the pellets were consumed, feed bags
were removed. Weekly serum samples and a day 28 GM muscle
biopsy specimen were obtained but not analyzed in the present study.
On day 56, the same day 0 sampling protocol was repeated.
2.1.3 | 3-Dimensional scanning
Three-dimensional scanning was performed by the same individual
(A. B.) as previously described to determine the volume of muscle over
the caudal thorax and hindquarters termed “torso.”18 Scans were per-
formed in duplicate with <3.5% error between duplicate scans. Briefly,
the tail was wrapped and a lunging surcingle was fitted into the natu-
ral girth groove to define the cranial margin of the torso. Xylazine
hydrochloride (0.3-0.4 mg/kg IV) was administered to horses that
were reluctant to stand still. An Occipital Structure Sensor (Structure
v1.9, Occipital, Inc, Boulder, Colorado) was attached to an iPad Air
2 running the Structure application (Structure v1.9, Occipital, Inc) and
linked to a laptop computer that ran the Skanect scanning program
(Skanect Pro v1.9 [Win64], Occipital, San Francisco, California).
Horses were scanned while the operator with the handheld scanner
moved around the horse, which was standing squarely. Object files
for each scan were exported from Skanect and imported into the
Meshmixer program (Version 3.3.15, Autodesk, Inc, San Francisco,
California). The horse's torso then was isolated in each scan by
cropping. The torso was delineated cranially by the surcingle and ven-
trally by a plane drawn parallel to the floor from the junction of the
flank and stifle to the surcingle. Torso volume was calculated for each
horse on days 0 and 56 as a representation of muscle mass. To ensure
volume changes were not the result of increased fat deposition, mea-
surement of SC adipose tissue depth was performed at days 0 and
56 using an ultrasound examination (TeraVet 3000; Teratech Corpo-
ration, Burlington, Massachusetts) at a site 5 cm to the left and right
of the root of the tail. A linear 6-MHz probe (Terrason, Teratech
Corporation) was oriented transversely, and fat depth was measured
from the skin surface to the ventral limit of the SC adipose tissue.
Right and left values were averaged.
2.1.4 | Serum samples
Jugular venous blood samples were collected into vacutainer, immedi-
ately placed on ice and protected from sunlight. Samples were collected
just before the scheduled time for supplement administration. Serum
was separated within 6 hours and stored at −80C until analyzed at the
conclusion of the study. Alpha-tocopherol analysis was performed at the
University of California, Davis, using high-performance liquid chromatog-
raphy as previously described.11
2.1.5 | Muscle biopsies
Horses were sedated with xylazine (0.5-1.1 mg/kg IV) or detomidine
(0.005-0.02 mg/kg IV). Subcutaneous muscle biopsy specimens were
obtained using an open surgical technique alternating sides for days
0 and 56. A site 1 cm abaxial to dorsal midline extending 6 cm cranially
from the tail head was clipped, surgically sterilized, and 4 mL of 2% lido-
caine was injected SC. A 4-cm incision was made in the skin and fascia,
which then were retracted to expose the underlying muscle. A 2-cm
cube of muscle was removed and SC tissue and skin sutured. Horses
were given 1.1 mg/kg IV flunixin meglumine after the biopsy.
Gluteus medius biopsies were performed as previously described
using a modified Bergstrom needle at a site approximately 8 cm cau-
dal to the tuber coxae, along a line from the top of the tuber coxae to
the tail head.15,19 Samples for histopathology were obtained from the
right GM on day 0, a second sample that was snap frozen for future
molecular analyses was obtained on day 28 from the left GM and, on
day 56, samples for histopathology were obtained from the right
GM. Samples for muscle histopathology were frozen in isopentane
suspended in liquid nitrogen within 4 hours of sampling. Samples for
electron microscopy (EM) were placed in 2.5% glutaraldehyde in
0.1 M sodium cacodylate buffer.
2.1.6 | Muscle histopathology and morphometry
Seven micron-thick cross-sections of SC and GM muscle were stained
with hematoxylin and eosin (HE), modified Gomori Trichrome, succi-
nate dehydrogenase (SDH), nicotinamide adenine dinucleotide tetra-
zolium reductase (NADH-TR), and myosin adenosine triphosphatase
with preincubation at pH 4.4.20 One researcher (S.J.V.) masked to
sample identity including time and treatment conducted the histo-
pathologic evaluations.
A minimum of 150 muscle fibers (range, 150-378) per muscle
biopsy specimen were examined to determine the number of muscle
fibers with “moth-eaten” staining, aggregates of subsarcolemmal mito-
chondria, anguloid atrophy, and angular atrophy using 10× images of
NADH-TR stains. The presence of “moth-eaten” fibers was confirmed
by examination of SDH stains. Percentages of fibers for each variable
were calculated and mitochondrial alterations compared to the reference
range (<2.5% mitochondrial alterations). The reference range used by the
Neuromuscular Diagnostic Laboratory at Michigan State University rep-
resents the mean ± 2 standard deviations for mitochondrial alterations in
6 SC samples previously taken from healthy Quarter Horses with normal
serum and muscle α-TP concentrations. The reference population
included 4 geldings and 2 mares with an average age of 8 ± 2 years.
Muscle fiber compositions were determined for SC and GM mus-
cle samples by typing at least 250 fibers that stained for type 1, type
2A, and type 2X in ΑTPase stains. The cross-sectional area of muscle
fibers was measured using Image J software (https://imagej.nih.gov/
ij/) to outline the sarcolemma of >100 fibers of each type (if present)
that were in precise cross section, avoiding any obliquely sectioned
fibers. Mean areas were calculated for each fiber type, and the mean
area of all fibers examined per sample also was calculated.
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2.1.7 | Electron microscopy
Seven randomly selected SC samples from day 56, including 3 C and
4 Tx horses, were subjectively evaluated by EM for the presence of
lipopigment, lipofuscin, dense bodies, honeycomb tubular structures,
mitochondrial size and shape, myofibril size, and myofibril density.
2.2 | Retrospective study
2.2.1 | Retrospective VEM case selection
The database of the Neuromuscular Diagnostic Laboratory at Michigan
State University was searched from December 2018 and dating backward
to January 2016 to identify 10 cases of VEMwith SC muscle samples sub-
mitted to the Neuromuscular Diagnostic laboratory that were well pre-
served, in cross section, and had minimal artifact from shipping. Seven of
the 10 rVEM horses had concurrent GM (n = 5) or semimembranosus
(SM; n = 2) muscle samples submitted, and these also were evaluated.
2.2.2 | VEM histopathology
Slides of SC and GM or, if submitted, SM muscles were evaluated for
the percentage of fibers with histopathologic changes in the same
manner as for the prospective trial with a range of 164 to 277 fibers
scored. The person scoring each retrospective clinical sample was
blinded to the details of the case. Comparisons of the percentage of
fibers with mitochondrial alterations and atrophy in the rVEM cases
were made using values for all prospective horses on day 0. Two
rVEM horses had SC and GM samples frozen within 4 hours of sam-
pling, and fiber sizes were determined for these cases. Fiber sizes
were not assessed in shipped samples because they develop artifac-
tual fiber swelling.21 Electron microscopy was performed on SC from
1 rVEM case that had been immediately placed in glutaraldehyde.
2.3 | Statistical analysis
Data were evaluated for normal distribution using the Kolmogorov-
Smirnov test. In the prospective study, data for age, body weight, torso
volume, serum α-TP and SC muscle were normally distributed. Log10
transformation was performed on tail head fat depth and GM type 2X
fiber size because data were not normally distributed. Data that were
expressed as proportions and not normally distributed (GM anguloid
atrophy, GM mitochondrial aggregation) was transformed using the arc-
sine of the square root of the proportion before analysis. One prospec-
tive muscle biopsy specimen from the SC and 1 from GM muscle could
not be analyzed because of excessive freeze artifact. The effect of time
(day 0 versus day 56) within Tx and C groups, respectively, was evalu-
ated using a mixed effects model, with time and treatment as fixed vari-
ables and horse as the random variable. Post hoc testing was performed
using a Sidak's multiple comparison test and P was set at <.05.
For retrospective data, an unpaired Student's t test (normally dis-
tributed data; subsarcolemmal aggregates, percentage mitochondrial
change, anguloid atrophy) or Mann-Whitney test (nonnormally
distributed data; “moth-eaten” fibers and angular atrophy) was used
to compare data from rVEM cases with day 0 prospective horses
using a Bonferroni corrected P < .01 (n = 5 variables). Statistical analy-
sis was performed using GraphPad Prism version 8.0 for Windows
(GraphPad, San Diego, California).
3 | RESULTS
3.1 | Prospective study
3.1.1 | Horses
No significant difference was found in the age or sex of horses in C
and Tx groups. All horses had normal physical and neurologic exami-
nation findings on days 0 and 56 and subjectively appeared to have
normal muscle mass.
3.1.2 | Serum α-TP
Mean serum α-TP concentrations did not change between day
0 (1.46 ± 0.63 μg/mL) and day 56 (1.29 ± 0.67 μg/mL) for the C group
(reference range, > 3 μg/mL).6 In contrast, serum α-TP concentrations
increased significantly in the Tx group (day 0, 1.17 ± 0.34 μg/mL; range,
0.70-1.71 μg/mL; day 56, 2.56 ± 0.54 μg/mL; range, 1.70-3.39 μg/mL;
P < .0001) with only 1 horse still having a concentration < 2.0 μg/mL.
3.1.3 | Body weight and volume
Weight did not change significantly between days 0 and 56 for C (day
0, 548 ± 56 kg; day 56, 563 ± 40 kg) or Tx groups (day 0, 522 ± 50 kg;
day 56, 540 ± 50 kg). Tail head fat depth did not change significantly
between days 0 and 56 for either C (day 0, 1.66 ± 0.28 cm; day 56, 1.90 ±
0.62 cm) or Tx groups (day 0, 1.71 ± 0.66 cm; day 56, 1.71 ± 0.70 cm).
The mean torso volume did not change between days 0 and 56 for either
the C (day 0, 0.2823 ± 0.0228 m3; day 56, 0.2874 ± 0.0242 m3) or Tx
groups (day 0, 0.2679 ± 0.0215 m3; day 56, 0.2723 ± 0.0219 m3).
3.1.4 | Sacrocaudalis muscle histopathology
A mean of 231 ± 37 SC fibers were evaluated. Mitochondrial alter-
ations in amounts above the upper limit of the established reference
range (2.5% of fibers) were present in the SC samples at day 0 in 3 of
8 C horses (4.1%, 4.5%, and 5.8% of fibers) and 4 of 8 C horses at day
56 (3.4%, 5.8%, 6.5%, and 8.5% of fibers; Table 1; Figure 1A-D). For
the Tx group, the same 3 horses had mitochondrial alterations above
the reference range at days 0 and 56 (day 0: 2.5%, 3.5%, and 3.9% of
fibers; day 56: 3.1%, 3.1%, and 9.8% of fibers). Between days 0 and
56, no significant differences were found in the percentages of
“moth-eaten” fibers, fibers with aggregates of subsarcolemmal mito-
chondria, or anguloid atrophied fibers in either the C or Tx groups
(Table 1). The number of angular atrophied fibers was very small, and
significantly fewer angular atrophied fibers were found in the control
group on day 56 (0.0) compared to day 0 (0.3%; P = .04; Table 1).
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3.1.5 | Gluteus medius muscle histopathology
A mean of 166 ± 11 GM fibers were morphologically evaluated. No
fibers had a “moth-eaten” appearance or subsarcolemmal mitochondrial
aggregates at day 0, and no significant change in mitochondrial alter-
ations occurred between days 0 and 56 in either C or Tx horses
(Table 1). Fewer than 5% of muscle fibers showed anguloid atrophy at
day 0 (Table 1), and no significant change occurred in the percentage of
anguloid atrophied fibers for either C or TX groups by day 56 (Table 1). A
significant increase occurred in angular atrophied fibers between days 0 and
56 in the C (P = .01) but not the Tx group (P = .25; Table 1). In 3 C and 4 Tx
horses on day 56, repeat biopsy samples of the right GM had focal fascicles
with pronounced anguloid and angular atrophied type 1, type 2A, and type
2X fibers (Figure S1). These fibers had peripherally located nuclei in
HE-stained sections, and some fibers had subsarcolemmal mitochon-
drial aggregates (Figure S1). The focal extent of atrophy resembled
neurogenic atrophy that could have arisen from damage to a nerve
branch during the previous biopsy of the right GM. Images obtained
to measure muscle fiber areas included these focal areas of atrophy.
3.1.6 | Muscle fiber type composition and
morphometry
The SC muscle had a high proportion of large type 1 muscle fibers
(>86%) with few type 2A fibers and rare type 2X fibers (Table 2) with no
significant differences between days 0 and 56. In contrast, the GM mus-
cle had a high proportion of type 2A and 2X fibers and, on average,
<16% type 1 fibers (Table 2). The fiber type compositions and cross-
sectional areas of muscle fibers in the SC and GM muscle did not differ
significantly between days 0 and 56 in either C or Tx groups (Table 2).
3.1.7 | Electron microscopy
Samples for EM included 2 C and 3 Tx horses that did not have light
microscopic mitochondrial alterations affecting >2.5% of fibers and 1 C
and 1 Tx horse with light microscopic mitochondrial alterations affecting
≥2.5% of fibers. Granular lipopigment and lipofuscin and lysosomes laden
with lipofuscin were present in all seven SC samples of C and Tx horses
(Figure 2A, B). Mitochondria in 2 of 4 Tx and 2 of 3 C samples were small
and present in large numbers under a scalloped sarcolemma (Figure 2B).
Degenerating mitochondrial cristae were observed in 1 Tx and 1 C sam-
ple. One Tx sample with 2.4% mitochondrial alterations contained dense
bodies and honeycomb-shaped tubular structures (Figure 2C).
3.2 | Retrospective VEM cases
3.2.1 | Horses
Of the 10 VEM cases that met our inclusion criteria, 7 different breeds
were represented, and included Belgian Warmblood (n = 2), Quarter
Horse (n = 2), Paint (n = 1), Arabian (n = 1), Clydesdale Cross (n = 1),
Rocky Mountain Horse (n = 1), and mixed breed (n = 2). There were
6 geldings and 4 mares with a mean age of 11.7 ± 3.5 years (range,
6-15 years of age). Serum creatine kinase activities reported for 5 of
10 horses were all in the normal range, with a mean of 169 ± 60 U/L
(reference, 82-303 U/L). Serum α-TP concentrations were reported for
9 of 10 horses, with a mean of 2.3 ± 1.1 μg/mL (range, 0.8-3.9 μg/mL).
Clinical signs in the rVEM horses included muscle atrophy, fasciculations,
weakness and, in 3 horses, a gait abnormality resembling mild shivers or
stringhalt. Muscle mass was reported (n = 3) or directly observed by
investigators (n = 5) to be decreased in 8 horses. In 1 horse, a gait abnor-
mality and trembling were the primary presentating findings, and in
1 horse poor performance was the primary complaint. Recommendations
were to treat with 5000 IU/day of water-dispersible RRR α-TP, and
follow-up emails were received in April 2019 for 9 of 10 cases. All
owners felt that horses had normal muscle mass on follow-up, with the
exception of 1 horse that was euthanized because of suspensory liga-
ment desmitis without ever having received vitamin E.
TABLE 1 The percentage of fibers with histopathologic features of moth-eaten fibers, subsarcolemmal aggregates of mitochondria (subsarc.
mitochondria), all mitochondrial alterations (sum of moth-eaten + subsarcolemmal aggregates; mitochondrial alterations), anguloid and angular
atrophy in the sacrocaudalis dorsalis medialis and gluteus medius muscles in control horses (C) and horses treated with 5000 IU/day of water
dispersible α-TP (Tx) at day 0 and day 56 of the treatment trial
Group N Moth eaten (%)
Subsarc.
Mitochondria (%)
Mitochondrial
alterations (%)
Anguloid
atrophy (%)
Angular
atrophy (%)
Sacrocaudalis
Reference 6 0.0 ± 0.0 0.9 ± 0.8 0.9 ± 0.8 4.3 ± 1.6 0.0 ± 0.0
C day 0 8 1.4 ± 1.2 1.2 ± 0.9 2.6 ± 1.9 4.1 ± 3.2 0.3 ± 0.3a
C day 56 8 1.7 ± 2.2 1.1 ± 1.1 3.2 ± 3.3 4.0 ± 2.6 0.0 ± 0.0
Tx day 0 8 1.1 ± 0.8 1.0 ± 0.6 2.1 ± 1.2 7.5 ± 2.7 0.4 ± 0.3
Tx day 56 8 1.5 ± 2.6 1.2 ± 0.9 2.7 ± 3.1 7.2 ± 2.5 0.2 ± 0.3
Gluteal muscle
C day 0 8 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 2.5 ± 1.5 0.1 ± 0.2a
C day 56 8 0.0 ± 0.0 1.5 ± 2.0 1.5 ± 2.0 9.5 ± 11.2 6.3 ± 9.4
Tx day 0 8 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 1.7 ± 1.2 0.0 ± 0.0
Tx day 56 8 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 3.0 ± 1.9 1.8 ± 3.4
aA significant difference between C day 0 and C day 56.
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3.2.2 | Sacrocaudalis muscle histopathology
A mean of 221 ± 34 SC fibers were scored for rVEM horses. Histo-
pathologic lesions were more pronounced in the SC muscle of rVEM
horses than in the day 0 prospective subclinical horses (Figures 1E, F
and 3). A significantly higher percentage of muscle fibers in rVEM
horses had “moth-eaten” staining, mitochondrial aggregates, total
mitochondrial alterations, and anguloid atrophy compared to prospec-
tive day 0 samples (Figure 3A-C). Angular atrophied fibers were rare
at <3% of fibers in rVEM horses with no significant difference in
percentage of angular atrophied fibers compared to day 0 prospective
horses (Figure 3D).
3.2.3 | GM/SM muscle histopathology
A mean of 221 ± 30 GM fibers were scored for rVEM horses. “Moth-
eaten” fibers were not present in the GM muscle of any rVEM horses
(Figures 3C, E and 4). Significantly more mitochondrial aggregates,
mitochondrial alterations, and anguloid atrophied fibers were present
F IGURE 1 Cross sections of sacrocaudalis dorsalis medialis muscle stained with NADH-TR. Bar in (A, C, E) indicated 100 μm. Bar in (B, D, F)
indicates 50 μm. A, Muscle fibers from a day 0 subclinical α-TP-deficient horse showing a normal staining pattern (×20). B, Higher power view of
the normal staining pattern of myofibers (×40). C, Muscle fibers from a day 0 subclinical α-TP-deficient horse containing moth-eaten fibers
(vertical arrow) and anguloid atrophied fibers (horizontal arrow) (×20). D, Higher power view showing a moth-eaten fiber (vertical arrow) and
fibers with subsarcolemmal mitochondrial aggregates (×40). E, Cross section of muscle from a retrospective VEM case showing a larger number of
fibers with a more marked moth-eaten staining pattern (vertical arrow) and anguloid atrophied fibers (horizontal arrow) (×20). F, Higher power
view of a moth-eaten fiber with central pallor (vertical arrow) and more marked anguloid atrophy (horizontal arrow) in a retrospective VEM case
(×40). NADH-TR, nicotinamide adenine dinucleotide tetrazolium reductase; VEM, vitamin E-responsive myopathy
TABLE 2 Sacrocaudalis dorsalis medialis (SC) and gluteus medius (GM) muscle fiber type composition and cross-sectional areas in control
horses (C) and horse treated with 5000 IU/day of water dispersible α-TP (Tx) for 56 days
Group N Type 1 (%) Type 2A (%) Type 2X (%)
Area
Type 1 (μm2) Type 2A (μm2) Type 2X (μm2) All fibers (μm2)
Sacrocaudalis
C day 0 8 90 ± 14 10 ± 14 5222 ± 1719 5807 ± 3156 5239 ± 1744
C day 56 8 86 ± 10 14 ± 10 5683 ± 899 4223 ± 1866 5514 ± 995
Tx Day 0 8 87 ± 11 13 ± 1 4686 ± 957 3219 ± 1184 4563 ± 1012
Tx Day 56 8 85 ± 6 15 ± 6 5544 ± 980 4548 ± 1837 5414 ± 837
GM
C day 0 8 12 ± 5 19 ± 6 69 ± 10 2054 ± 584 2555 ± 454 5085 ± 1033 3233 ± 801
C day 56 8 10 ± 2 18 ± 7 72 ± 6 1843 ± 802 2121 ± 671 3988 ± 884 2738 ± 648
Tx day 0 8 16 ± 8 26 ± 10 60 ± 14 2268 ± 561 3270 ± 1036 5388 ± 1876 3354 ± 777
Tx day 56 8 13 ± 3 24 ± 8 63 ± 10 1930 ± 534 2550 ± 493 5583 ± 1303 2651 ± 836
No significant differences were identified.
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in rVEM horses compared to day 0 prospective subclinical horses
(Figure 3F, G). The percentage of angular atrophied fibers did not dif-
fer between VEM and day 0 horses (Figure 3H).
3.2.4 | Muscle fiber composition and cross-sectional
areas
For the 2 rVEM horses with samples frozen soon after biopsy
(Figure 4), fiber compositions in SC were 83% and 75% in type 1 and
17% and 25% in type 2A. Compared to day 0 horses (5012
± 1421 μm2; Figure 4A, B), the overall SC muscle fiber cross-sectional
areas for these 2 rVEM horses were 6% to 9% smaller (4783 and
4544 μm2; Figure 4C-F). The GM fiber type compositions were 17%
and 11% in type 1; 40% and 21% in type 2A; and 43% and 69% in
type 2X, respectively, in the 2 rVEM horses. Compared to day 0 horses
(3520 ± 764 μm2), the overall GM muscle fiber cross-sectional areas
in the 2 rVEM horses were similar for 1 rVEM horse (Figure 4C;
F IGURE 2 Electron microscopy. A, Four lysosomes laden with lipofuscin (horizontal arrow) and lipid droplets in a prospective day 56 horse
treated with α-TP (bar = 0.5 μm). B, Accumulation of lipopigment, (horizontal arrow) and pleomorphic small mitochondria (vertical arrow) under a
scalloped sarcolemma (gray vertical arrow) in a day 56 horse treated with α-TP (bar = 1 μm). C, Honeycomb-like tubular structures (arrows) under
the sarcolemma of a day 56 horse treated with α-TP (bar = 0.5 μm). D, Longitudinal segments of two adjacent myofibers, one normal (N) and one
atrophied (A) in a retrospective VEM horse. The atrophied fiber contains thin myofibrils with gaps between myofibrils and small subsarcolemmal
mitochondria aggregating under a scalloped sarcolemma (bar = 2 μm). α-TP, alpha-tocopherol; VEM, vitamin E-responsive myopathy
F IGURE 3 The percentage of fibers in the sacrocaudalis dorsalis medialis (SC) of prospective subclinical α-TP-deficient horses on day 0 and in
clinical rVEM horses with histological features of (A) moth-eaten fibers; (B) subsarcolemmal mitochondrial aggregates; (C) anguloid fibers; and
(D) angular fibers. The percentage of fibers in the gluteus medius (GM) muscle of prospective subclinical α-TP-deficient horses on day 0 and in
clinical rVEM horses with histological features of (E) moth-eaten fibers; (F) subsarcolemmal mitochondrial aggregates; (G) anguloid fibers; and
(H) angular fibers. α-TP, alpha-tocopherol; rVEM, responsive vitamin E-responsive myopathy
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3544 μm2) and 20% smaller in the other rVEM horse (Figure 4E;
2752 μm2).
3.2.5 | Electron microscopy
In the 1 rVEM SC sample processed, granular lipopigment and deposits
of lipofuscin were evident in numerous fibers. Many muscle fibers were
atrophic with sparse numbers of thin myofibrils creating expanded gaps
between myofibrils (Figure 2D). Membranous whirls and accumulations
of small pleomorphic mitochondria were evident under the sarcolemma,
which often had a scalloped appearance (Figure 2D).
4 | DISCUSSION
In our study, light microscopic alterations in mitochondrial staining were
present in SC muscle fibers of subclinical α-TP-deficient horses. Mito-
chondrial alterations were more abundant in clinically affected rVEM
horses, which had 5 times more fibers with mitochondrial alterations
(range, 6%-23%) compared to subclinical α-TP-deficient horses (day 0:
range, 0%-6% of fibers). Mitochondrial alterations consisted of sub-
sarcolemmal aggregates of mitochondria and a “moth-eaten” staining pat-
tern in muscle fibers. Mitochondrial alterations were restricted to the SC
muscle of horses with subclinical α-TP deficiency, but subsarcolemmal
aggregates of mitochondria were present in the SC and GM/SM of rVEM
horses. “Moth-eaten” fibers, which represent multifocal zones that lack
mitochondria,22 only were observed in the SC muscle of subclinical and
clinical α-TP-deficient horses. The reason why the SC muscle most read-
ily displays mitochondrial staining abnormalities with α-TP deficiency
could be related to the predominance of oxidative type 1 fibers in the SC
(67%-100%) but not the GM (4%-22%) muscle. Our results concur with
those of previous studies that showed that the SC muscle is most likely
to show histopathologic lesions associated with α-TP deficiency.15,16 Our
results provide additional information indicating that mitochondrial alter-
ations can be present in <6% of fibers of SC muscle with subclinical α-TP
deficiency, whereas mitochondrial alterations in ≥6% of SC fibers appear
to be associated with clinical evidence of grossly apparent muscle
atrophy.
The basis for mitochondrial alterations with α-TP deficiency is
likely lipid peroxidation of mitochondrial membranes because of an
inability of α-TP-deficient muscle to scavenge peroxyl radicals faster
than they can react with lipids or proteins.23 The mitochondrial elec-
tron transport chain is the major source of reactive oxygen species in
skeletal muscle, and α-TP is the primary antioxidant found in the lipid
bilayer.1,24 Membrane damage in the SC muscle of horses in the pre-
sent study was evident on EM as membranous whirls, dense bodies,
and honeycomb-like elements, all features previously described in
α-TP-deficient rats.25 Mitochondrial membrane damage decreases the
stability of mitochondrial membranes, which results in a significantly
decreased metabolic rate, reflected by decreased NADH and FADH2
F IGURE 4 Cross sections of gluteal muscle stained with NADH-TR (bar = 100 μm) and view of the hindquarter muscling of the respective
horse. A, Muscle fibers with a normal mosaic staining pattern of oxidative and non-oxidative fibers in a prospective α-TP-deficient horse on day
56 (×20). B, Normal muscling of the same Quarter Horse as in (A). C, Increased fiber size variation apparent in the gluteal muscle of a
retrospective VEM horse (×20). D, Note the atrophy of the biceps femoris (white arrow), middle (red arrow), and superficial (black arrow) gluteal
muscles in the same horse as shown in (C). E, Mild subsarcolemmal mitochondrial aggregates, anguloid atrophy, and smaller cross-sectional area
of gluteal muscle fibers in another retrospective VEM horse (×20). F, Note the atrophy of the biceps femoris (white arrow), middle (red arrow),
and superficial (black arrow) gluteal muscles in the horse represented in (E). NADH-TR, nicotinamide adenine dinucleotide tetrazolium reductase;
α-TP, alpha-tocopherol; VEM, vitamin E-responsive myopathy
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utilization and decreased activity of respiratory chain complexes.25
Decreased oxidative capacity with α-TP deficiency could account for
some of the reported muscle weakness and decrease in exercise per-
formance in VEM horses.
An additional feature of the SC muscle in all subclinical and clinical
rVEM horses examined was the presence of lipofuscin, a recognized fea-
ture in the retina, central nervous system, gastrointestinal tract, and liver
of EMND α-TP-deficient horses.5 Lipofuscin is oxidized protein and lipid,
and its accumulation in cells is both age- and oxidative stress-
dependent.26 The accumulation of lipofuscin in subclinical α-TP-deficient
horses with or without abnormal mitochondrial staining may represent
oxidative damage occurring at an early stage of α-TP deficiency in
horses. Because lipofuscin accumulates as cells age, we could not rule
out the possibility that lipofuscin was present merely as a reflection of
age. Lipofuscin itself can become a pro-oxidant because of its ability to
incorporate redox-active metals such as iron.26 As lipofuscin accumulates
in lysosomes, it triggers a cycle of progressive accumulation of protein
oxidation products that impair autophagocytic capacity.26 Impairment of
mitophagy in muscle cells, which are post-mitotic and therefore unable
to permanently remove cellular debris, could explain the persistent alter-
ations in mitochondrial staining in day 56 samples. Whether a longer
duration of Tx or a different dose of α-TP would have resulted in normal
mitochondrial morphology was not established. The potentially irrevers-
ible mitochondrial damage that was present in subclinical and clinically
affected VEM horses suggests that assessing α-TP concentrations and
preventing α-TP deficiency in clinically normal horses may be advanta-
geous to preserve oxidative muscle fiber function.
Acute or chronic onset of grossly apparent muscle atrophy is a
hallmark of clinical VEM that impacts many different breeds including
Quarter Horses used in the prospective study.15 The presence of
grossly apparent muscle atrophy was associated with progressive
atrophic alteration in fiber shapes. Horses with clinical VEM in our
study had significantly more anguloid atrophied fibers than did sub-
clinical day 0 α-TP-deficient horses. For example, rVEM horses had
anguloid atrophy in 16% of SC and 10% of GM fibers, whereas at day
0, subclinical α-TP-deficient horses had a mean of 6% SC and 2% GM
fibers with anguloid atrophy. Anguloid atrophy previously has been
reported with VEM, and anguloid atrophy is most characteristic of
myogenic rather than neurogenic disorders.15,27 Angular atrophy was
rare in our study, with an average of <0.5% of fibers in SC and GM
muscles of day 0 α-TP-deficient horses showing angular atrophy and
an average of 0.9% of SC and 0.5% of GM fibers having angular atro-
phy in rVEM horses. Angular atrophy was found in focal regions of
some of the day 56 GM specimens that were not present in day 0 GM
biopsy specimens. This finding appeared to be a result of obtaining
day 56 biopsy specimens on the same side, and too close to the site
of day 0 specimens, apparently damaging focal nerve branches.
Smaller fibers at this site also could have been a result of regenera-
tion, but this was less likely based on the absence of large internalized
myonuclei and basophilia typical of regeneration.22
In general, grossly apparent muscle atrophy occurs when the physio-
logical balance between protein synthesis and breakdown is disrupted.
This balance has been proposed to be redox-sensitive with 1 mechanism
for atrophy occurring when oxidative stress induces both expression and
activity of components of the ubiquitin-proteasome-dependent proteo-
lytic pathway.2,24 The trigger for muscle atrophy in the rVEM horses
could be related to the extent of oxidative stress, the total balance of
other antioxidants such as glutathione, thioredoxins, catalase, and super-
oxide dismutase, and the duration of antioxidant deficiency in skeletal
muscle.23 In mouse models of disuse atrophy, supplementation with
α-TP has been shown to downregulate genes involved in muscle proteol-
ysis such as μ calpain, caspases-3, -9, and -12, and 2 atrophy-related
ubiquitin ligases (MuRF1 and MAFbx).28 Thus, in horses with gross mus-
cle atrophy, α-TP supplementation likely reestablishes normal muscle
mass by inhibition of proteolysis. In our study, the lack of an increase in
skeletal muscle volume or muscle fiber cross-sectional areas with α-TP
supplementation of normal-appearing α-TP-deficient horses supports the
view that α-TP inhibits proteolysis rather than enhancing muscle protein
synthesis.
In conclusion, mitochondrial alterations in <6% of SC fibers are evi-
dent in apparently healthy α-TP-deficient horses and do not resolve after
56 days of 5000 IU/day of α-TP supplementation. Grossly apparent
muscle atrophy in clinical VEM occurred in horses with ≥6% (mean 13%)
of SC fibers showing alterations on mitochondrial stains. Serum α-TP
deficiency appears to be associated with persistent mitochondrial alter-
ations that, once beyond a certain threshold, are associated with grossly
apparent muscle atrophy.
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